David M. Rothstein
ActivBiotics
Inc, Lexington
USA
Name/email consistency: high
- Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae. Rothstein, D.M., Suchland, R.J., Xia, M., Murphy, C.K., Stamm, W.E. J. Antibiot. (2008)
- Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization. Rothstein, D.M., Mullin, S., Sirokman, K., Söndergaard, K.L., Johnson, S., Gwathmey, J.K., van Duzer, J., Murphy, C.K. J. Antibiot. (2008)
- Histatin-derived peptides: potential agents to treat localised infections. Rothstein, D.M., Helmerhorst, E.J., Spacciapoli, P., Oppenheim, F.G., Friden, P. Expert. Opin. Emerg. Drugs (2002)
- Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Rothstein, D.M., Spacciapoli, P., Tran, L.T., Xu, T., Roberts, F.D., Dalla Serra, M., Buxton, D.K., Oppenheim, F.G., Friden, P. Antimicrob. Agents Chemother. (2001)